Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent androgen deprivation: clinical experience and practical applications.

Jonathan L Wright1, Celestia S Higano, Daniel W Lin

  • 1Department of Urology, University of Washington, Seattle, WA 98195, USA. dlin@u.washington.edu

The Urologic Clinics of North America
|April 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer.

The oncologist·2026
Same author

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

International urology and nephrology·2026
Same author

Estimating optimally tailored active surveillance strategy under interval censoring.

Biometrics·2025
Same author

Comparing virtual and in-person training for intracavernosal injection therapy in a multidisciplinary sexual health clinic within a prostate cancer survivorship program.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study.

Journal of the National Cancer Institute·2025
Same author

Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.

The Journal of urology·2025

Intermittent androgen deprivation (IAD) offers a potential alternative to continuous androgen deprivation (CAD) for prostate cancer patients, aiming to improve quality of life and delay disease progression. Ongoing trials are evaluating its efficacy and feasibility compared to traditional treatments.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer diagnosis is occurring at younger ages, while mortality occurs at older ages.
  • Men are increasingly treated with androgen deprivation for biochemical relapse, extending treatment duration.
  • Intermittent androgen deprivation (IAD) is explored as an alternative to continuous androgen deprivation (CAD).

Purpose of the Study:

  • To review the theoretical benefits and rationale behind IAD.
  • To summarize completed and ongoing trials investigating IAD versus CAD.
  • To address practical applications, controversies, and future directions of IAD in prostate cancer management.

Main Methods:

  • Review of completed and ongoing multi-institutional, randomized trials.
  • Discussion of theoretical benefits and rationale for IAD.

Related Experiment Videos

  • Analysis of controversies and practical applications.

    • Main Results:

    • IAD is investigated to improve quality of life and delay androgen independence.
    • IAD may be an alternative to surgery or radiotherapy for specific patient groups.
    • Ongoing trials will provide insights into IAD's utility, efficacy, and feasibility.

    Conclusions:

    • IAD presents a potential strategy to mitigate side effects of prolonged androgen deprivation.
    • Further research and clinical trials are crucial to establish IAD's role in prostate cancer care.
    • IAD may offer a valuable treatment option, especially for men with comorbidities.